Trial Profile
Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Apraglutide (Primary)
- Indications Gastrointestinal disorders
- Focus Adverse reactions
- Sponsors GLyPharma Therapeutic; Therachon
- 24 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as per Business decision.
- 05 Feb 2018 New trial record